LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

Search

Penumbra Inc

Закрыт

СекторЗдравоохранение

287.04 0.71

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

280.26

Макс.

288.77

Ключевые показатели

By Trading Economics

Доход

6M

45M

Продажи

15M

339M

P/E

Средняя по отрасли

71.937

35.733

Рентабельность продаж

13.336

Сотрудники

4,500

EBITDA

1.9M

51M

Рекомендации

By TipRanks

Рекомендации

Активная покупка

Прогноз на 12 месяцев

+7.25% upside

Дивиденды

By Dow Jones

Следующий отчет о доходах

29 окт. 2025 г.

Рыночная статистика

By TradingEconomics

Рыночная капитализация

1.7B

11B

Предыдущая цена открытия

286.33

Предыдущая цена закрытия

287.04

Новостные настроения

By Acuity

100%

0%

358 / 371 Рейтинг в Healthcare

Техническая оценка

By Trading Central

Уверенность

Bearish Evidence

Penumbra Inc График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

9 сент. 2025 г., 23:37 UTC

Популярные акции

Stocks to Watch: Oracle, Wearable Devices, GameStop

9 сент. 2025 г., 20:41 UTC

Отчет

Oracle's Backlog Surges With Major Customer Deals in 1Q

9 сент. 2025 г., 20:30 UTC

Отчет

GameStop 2Q Sales, Profit Rise

9 сент. 2025 г., 23:19 UTC

Обсуждения рынка

ANZ Adds a Further 50 Bps in FOMC Cuts to Outlook -- Market Talk

9 сент. 2025 г., 21:35 UTC

Отчет

Oracle Stock Soars on Strong AI Backlog. Earnings Were Good Enough. -- Barrons.com

9 сент. 2025 г., 21:32 UTC

Отчет

Oracle's Backlog Swells With Big Customer Deals -- Update

9 сент. 2025 г., 21:02 UTC

Приобретения, слияния, поглощения

DHL Adds to Healthcare Logistics Services With Acquisition -- Update

9 сент. 2025 г., 20:50 UTC

Обсуждения рынка

Basic Materials Roundup: Market Talk

9 сент. 2025 г., 20:33 UTC

Отчет

These Stocks Moved the Most Today: Apple, UnitedHealth, Nebius, Wolfspeed, Tourmaline Bio, Albemarle, Dell, and More -- Barrons.com

9 сент. 2025 г., 20:26 UTC

Отчет

Oracle Stock Soars on Strong Backlog. Earnings Were Good Enough. -- Barrons.com

9 сент. 2025 г., 20:23 UTC

Отчет

Oracle Stock Soars on Strong Backlog. Earnings Were Good Enough. -- Barrons.com

9 сент. 2025 г., 20:12 UTC

Отчет

Oracle Stock Jumps on Mixed Earnings Report -- Barrons.com

9 сент. 2025 г., 20:10 UTC

Отчет

Oracle Expects Cloud Infrastructure Rev to Grow 77% to $18 B This Fiscal Yr >ORCL

9 сент. 2025 г., 20:10 UTC

Отчет

Oracle Expects to Sign-Up Several Additional Multi-B-dollar Customers and RPO Is Likely to Exceed Half-A-Trillion Dollars Over Next Few Mos

9 сент. 2025 г., 20:09 UTC

Отчет

Synopsys Sees 4Q Adj EPS $2.76-Adj EPS $2.80 >SNPS

9 сент. 2025 г., 20:09 UTC

Отчет

Synopsys Sees 4Q Loss/Shr 16c-Loss 27c >SNPS

9 сент. 2025 г., 20:08 UTC

Отчет

Oracle 1Q Short-term Deferred Rev Were $12.1 B >ORCL

9 сент. 2025 г., 20:08 UTC

Отчет

Oracle 1Q Operating Income Was $4.3 B >ORCL

9 сент. 2025 г., 20:08 UTC

Отчет

Oracle Expects MultiCloud Rev to Grow Substantially Every Qtr for Several Years >ORCL

9 сент. 2025 г., 20:08 UTC

Отчет

Synopsys Sees 4Q Rev $2.23B-$2.26B >SNPS

9 сент. 2025 г., 20:07 UTC

Отчет

Oracle Total Remaining Performance Obligations Up to $455 B >ORCL

9 сент. 2025 г., 20:06 UTC

Отчет

Oracle 1Q Software Revenue $5.72B >ORCL

9 сент. 2025 г., 20:06 UTC

Отчет

Synopsys 3Q Adj EPS $3.39 >SNPS

9 сент. 2025 г., 20:06 UTC

Отчет

Oracle 1Q Cloud Revenue $7.19B >ORCL

9 сент. 2025 г., 20:05 UTC

Отчет

Oracle 1Q Rev $14.93B >ORCL

9 сент. 2025 г., 20:05 UTC

Отчет

Oracle 1Q EPS $1.01 >ORCL

9 сент. 2025 г., 20:05 UTC

Отчет

Synopsys 3Q EPS $1.50 >SNPS

9 сент. 2025 г., 20:05 UTC

Отчет

Oracle 1Q Services Revenue $1.35B >ORCL

9 сент. 2025 г., 20:05 UTC

Отчет

Oracle 1Q Adj EPS $1.47 >ORCL

9 сент. 2025 г., 20:05 UTC

Отчет

Oracle 1Q Hardware Revenue $670M >ORCL

Сравнение c конкурентами

Изменение цены

Penumbra Inc Прогноз

Целевая цена

By TipRanks

7.25% рост

Прогноз на 12 месяцев

Средняя 306.29 USD  7.25%

Максимум 350 USD

Минимум 265 USD

Основано на мнении 16 аналитиков Wall Street, спрогнозировавших целевые цены для Penumbra Inc на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Активная покупка

16 ratings

12

Покупка

4

Удержание

0

Продажа

Техническая оценка

By Trading Central

288.28 / 292.9394Поддержка и Сопротивление

Краткосрочная

Bearish Evidence

Среднесрочная

Bullish Evidence

Долгосрочная

Weak Bullish Evidence

Настроения

By Acuity

358 / 371Рейтинг в Здравоохранение

Новостные настроения

Сильные свидетельства нисходящего тренда

Волатильность

Ниже среднего

Объем новостей (RCV)

Ниже среднего

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

$

О компании Penumbra Inc

Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX Select, BENCHMARK, BMX96, BMX81, DDC, SENDit, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization Device, aspiration tubing, and aspiration pump under the Penumbra RED, JET, ACE, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that includes the Penumbra Coil 400, a detachable coil that provides an alternative for the treatment of aneurysms and other complex lesions, as well as Penumbra SMART COIL, a detachable coil to treat patients with a wide range of neurovascular lesions; and POD400 and PAC400 brands. In addition, the company provides peripheral embolization products, such as Ruby Coil System consisting of detachable coils for peripheral applications; Penumbra LANTERN Delivery Microcatheter, a low-profile microcatheter with a high-flow lumen; POD (Penumbra Occlusion Device) System, a single device solution; and Packing Coil, a complementary device for use in other peripheral embolization products. Further, it offers an immersive 3D computer-based technology platform under the real immersive system brand; and neurosurgical tools, such as Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum. The company sells its products through direct sales organizations and distributors. Penumbra, Inc. was incorporated in 2004 and is headquartered in Alameda, California.
help-icon Live chat